Atlan-Gepner C - Search Results

1

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P. Chaillous L, et al. Among authors: atlan gepner c. Lancet. 2000 Aug 12;356(9229):545-9. doi: 10.1016/s0140-6736(00)02579-4. Lancet. 2000. PMID: 10950231 Clinical Trial.

2

Serum reg protein level is not related to the beta cell destruction/regeneration process during early phases of diabetogenesis in type I diabetes.

Christofilis MA, Carrere J, Atlan-Gepner C, Zevaco-Mattei C, Thivolet C, Baeza N, Figarella C, Vialettes B. Christofilis MA, et al. Among authors: atlan gepner c. Eur J Endocrinol. 1999 Oct;141(4):368-73. doi: 10.1530/eje.0.1410368. Eur J Endocrinol. 1999. PMID: 10526250

3

A cyclophosphamide-induced autoimmune diabetes.

Atlan-Gepner C, Bouabdallah R, Valero R, Coso D, Vialettes B. Atlan-Gepner C, et al. Lancet. 1998 Aug 1;352(9125):373-4. doi: 10.1016/S0140-6736(05)60474-6. Lancet. 1998. PMID: 9717935 No abstract available.

4

Diverging evolution of anti-GAD and anti-IA-2 antibodies in long-standing diabetes mellitus as a function of age at onset: no association with complications.

Hermitte L, Atlan-Gepner C, Mattei C, Dufayet D, Jannot MF, Christofilis MA, Nervi S, Vialettes B. Hermitte L, et al. Diabet Med. 1998 Jul;15(7):586-91. doi: 10.1002/(SICI)1096-9136(199807)15:7<586::AID-DIA624>3.0.CO;2-B. Diabet Med. 1998. PMID: 9686699

5

Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.

Hermitte L, Martin-Moutot N, Boucraut J, Barone R, Atlan-Gepner C, Seagar M, Pouget J, Kleisbauer JP, Couraud F, Vialettes B. Hermitte L, et al. Among authors: atlan gepner c. J Clin Immunol. 2000 Jul;20(4):287-93. doi: 10.1023/a:1006619820040. J Clin Immunol. 2000. PMID: 10939716

6

[When and why should anti-GAD antibodies by looked for in the non-insulin-dependent diabetic patient?].

Atlan-Gepner C, Vialettes B. Atlan-Gepner C, et al. Diabetes Metab. 1999 Jun;25(2):177-9. Diabetes Metab. 1999. PMID: 10443330 Review. French. No abstract available.

7

Constitutive impaired TCR/CD3-mediated activation of T cells in IDDM patients co-exist with normal co-stimulation pathways.

Nervi S, Atlan-Gepner C, Fossat C, Vialettes B. Nervi S, et al. Among authors: atlan gepner c. J Autoimmun. 1999 Sep;13(2):247-55. doi: 10.1006/jaut.1999.0313. J Autoimmun. 1999. PMID: 10479393

8

Specific immunotherapy for the prevention of diabetes: theoretical and practical aspects.

Vialettes B, Atlan-Gepner C, Hermitte L. Vialettes B, et al. Diabetes Metab Rev. 1993 Dec;9(4):251-5. doi: 10.1002/dmr.5610090405. Diabetes Metab Rev. 1993. PMID: 7924822 Review. No abstract available.

9

Specific deficiency of p56lck expression in T lymphocytes from type 1 diabetic patients.

Nervi S, Atlan-Gepner C, Kahn-Perles B, Lecine P, Vialettes B, Imbert J, Naquet P. Nervi S, et al. Among authors: atlan gepner c. J Immunol. 2000 Nov 15;165(10):5874-83. doi: 10.4049/jimmunol.165.10.5874. J Immunol. 2000. PMID: 11067948

10

Relationship between HLA-DQ and -DR genotypes and clinical characteristics in a French population of Type 1 diabetic patients.

Zevaco-Mattei C, Reviron D, Atlan-Gepner C, Botti G, Simonin G, Lassmann-Vague V, Vague P, Mercier P, Vialettes B. Zevaco-Mattei C, et al. Diabet Med. 1999 Mar;16(3):201-6. doi: 10.1046/j.1464-5491.1999.00043.x. Diabet Med. 1999. PMID: 10227564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters